# US 2024/0189490 A1 · Antimicrobial eluting airway devices

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189490 A1
- Document ID: US20240189490A1
- Status: Published application
- Kind: A1
- Application number: 18/553,893
- Filed: 2022-04-08
- Published: 2024-06-13
- Earliest claimed: 2021-04-08
- Assignees: The Children's Hospital of Philadelphia
- Applicants: The Children's Hospital of Philadelphia
- Inventors: Riccardo L. GOTTARDI; Matthew R. ARONSON
- Web page: https://patentgrep.com/patent/US20240189490A1

## CPC

- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61P 31/04: Antibacterial agents
- A61L 29/085: {Macromolecular materials}
- A61L 29/16: Biologically active materials, e.g. therapeutic substances {(A61L29/048 takes precedence)}
- A61L 31/048: {obtained by reactions only involving carbon-to-carbon unsaturated bonds (A61L31/041 takes precedence)}
- A61L 31/06: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds {(A61L31/041 takes precedence)}
- A61M 16/04: Tracheal tubes (catheters in general A61M25/00)
- A61M 16/0402: {Special features for tracheal tubes not otherwise provided for}
- A61M 25/0045: {multi-layered, e.g. coated (coating materials A61L29/08)}
- A61M 31/002: {Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time (artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50)}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61L 2300/25: Peptides having up to 20 amino acids in a defined sequence
- A61L 2300/252: Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L 2300/404: Biocides, antimicrobial agents, antiseptic agents
- A61L 2420/02: Methods for coating medical devices
- A61M 16/0409: {with mean for closing the oesophagus}
- A61M 16/0465: {Tracheostomy tubes; Devices for performing a tracheostomy; Accessories therefor, e.g. masks, filters}
- A61M 16/06: Respiratory or anaesthetic masks
- A61M 2025/0046: {Coatings for improving slidability}
- A61M 2025/0056: {provided with an antibacterial agent, e.g. by coating, residing in the polymer matrix or releasing an agent out of a reservoir}
- A61M 2202/203: Bacteria
- A61M 2202/206: Viruses
- A61M 2205/0205: Materials having antiseptic or antimicrobial properties, e.g. silver compounds, rubber with sterilising agent
- A61M 2205/0238: the material being a coating or protective layer
- A61M 2207/00: Methods of manufacture, assembly or production
- A61M 2209/06: Packaging for specific medical equipment
- A61M 2210/1028: Larynx
- A61M 2210/1032: Trachea
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

The present disclosure provides improved airway intervention devices that are coated with a material and contain an antimicrobial peptide. The devices are useful in controlling the microbial flora of the airway and preventing infections and conditions such as subglottic stenosis, pneumonia (VAP), laryngeal infection, post-operative dressing/packing-induced infection, upper airway infection, rhinosinusitis, choanal atresia, vocal fold injury and paralysis.

## Claims

### Claim 1

An airway intervention device where a surface of said device is coated with a material comprising one or more anti-microbial peptides (AMPs) and one or more hydrophobic and/or natural polymers.

### Claim 2 (depends on 1)

The device of claim 1, wherein said device is a tracheal tube, a stent, a mask, a tracheostomy tube, a catheter, an oral retainer, a balloon, a patch, or a packing material.

### Claim 3 (depends on 1)

The device of claim 1, wherein the polymer is poly-(lactic-co-glycolic acid), poly glycolic acid, poly lactic acid, poly (lactic-co-glycolic acid), or any combination thereof, or poly caprolactone, hydrogel, alginate, polyurethane, polyester, poly (ethylene terephthalate), poly anhydrides, poly orthoesters, poly beta-amino esters, chitosan, hyaluronic acid, cellulose, collagen, gelatin, silk fibroin, and/or cyclodextrin.

### Claim 4 (depends on 1)

The device of claim 1, wherein the one or more AMPs is/are an anionic peptide, a linear cationic α-helical peptide, a cationic peptide enriched in one or more of proline, arginine, phenylalanine, glycine or tryptophan, or a anionic/cationic peptide containing cysteine with at least one intrapeptide disulfide bond, and optionally may contain one or more feature selected from a β-hairpin structure, a cyclic peptide structure, enrichment in any natural amino acid, a noncanonical amino acid, self-assembly, or D, L or D/L enantiomeric amino acids.

### Claim 5 (depends on 4)

The device of claim 4, where the anionic peptide is a dermicidin or Maximin H5.

### Claim 6 (depends on 4)

The device of claim 4, wherein the linear cationic α-helical peptide is a halictine, a citropin, an aurein, a temporin, a macropin, a cecropin, an andropin, a moricin, a ceratoxin, a melittin, a magainin, a dermaseptin, a bominin, brevinin-1, an esculentin, buforin II, a lassioglossin, CAP18 or LL37.

### Claim 7 (depends on 4)

The device of claim 4, wherein the cationic peptide enriched in one or more of proline, arginine, phenylalanine, glycine or tryptophan is an abaecin, a drosocin, an apidaecin, a diptericin, an attacin, a prophenin, or an indolicidin.

### Claim 8 (depends on 4)

The device of claim 4, wherein the anionic/cationic peptide containing cysteine with at least one intrapeptide disulfide bond is a brevenin, a protegrin, a tachyplesin, a defensin or a drosomycin.

### Claim 9 (depends on 1)

The device of claim 1, wherein the coated material permits controlled release of said AMP, such as 1 ng/day to 200 μg/day.

### Claim 10 (depends on 1)

The device of claim 1, wherein said material further comprising an anti-inflammatory agent, such as a steroid or an NSAID, or an additional molecule that impair a bacterial or viral agent, such as a protein that interferes with pathogen attachment, colonization, a protein that enhances immune clearance of said agent, or a conventional antibiotic, such as azithromycin, tobramycin, ciprofloxacin, erythromycin, and amoxicillin.

### Claim 11

A method of preparing a coated airway intervention device comprising:
(a) providing an airway intervention device;
(b) immersing said device in an emulsion comprising one or more hydrophobic or natural polymers and one or more anti-microbial peptides (AMPs) to coat said device;
(c) repeating step (b) at least once, optionally twice; and
(d) drying said coated device.

### Claim 12 (depends on 11)

The method of claim 11, wherein said device is a tracheal tube, a stent, a mask, a tracheostomy tube, a catheter, an oral retainer, a balloon, a patch, or a packing material.

### Claim 13 (depends on 11)

The method of claim 11, wherein the polymer is poly-(lactic-co-glycolic acid), poly glycolic acid, poly lactic acid, poly (lactic-co-glycolic acid), or any combination thereof, or is poly caprolactone, hydrogel, alginate, polyurethane, polyester, poly (ethylene terephthalate), poly anhydrides, poly orthoesters, poly beta-amino esters, chitosan, hyaluronic acid, cellulose, collagen, gelatin, silk fibroin, and/or cyclodextrin.

### Claim 14 (depends on 11)

The device of claim 11, wherein the one or more AMPs is/are an anionic peptide, a linear cationic α-helical peptide, a cationic peptide enriched in one or more of proline, arginine, phenylalanine, glycine or tryptophan, or a anionic/cationic peptide containing cysteine with at least one intrapeptide disulfide bond, and optionally may contain one or more feature selected from a β-hairpin structure, a cyclic peptide structure, enrichment in any natural amino acid, a noncanonical amino acid, self-assembly, or D, L or D/L enantiomeric amino acids.

### Claim 15 (depends on 14)

The method of claim 14, where the anionic peptide is a dermicidin or Maximin H5.

### Claim 16 (depends on 14)

The method of claim 14, wherein the linear cationic α-helical peptide is a halictine, a citropin, an aurein, a temporin, a macropin, a cecropin, an andropin, a moricin, a ceratoxin, a melittin, a magainin, a dermaseptin, a bominin, brevinin-1, an esculentin, buforin II, a lassioglossin, CAP18 or LL37.

### Claim 17 (depends on 14)

The method of claim 14, wherein the cationic peptide enriched in one or more of proline, arginine, phenylalanine, glycine or tryptophan is an abaecin, a drosocin, an apidaecin, a diptericin, an attacin, a prophenin, or an indolicidin.

### Claim 18 (depends on 14)

The method of claim 14, wherein the anionic/cationic peptide containing cysteine with at least one intrapeptide disulfide bond is a brevenin, a protegrin, a tachyplesin, a defensin or a drosomycin.

### Claim 19 (depends on 11)

The method of claim 11, wherein the coated material permits controlled release of said AMP, such as 1 ng/day to 200 μg/day.

### Claim 20 (depends on 11)

The method of claim 11, wherein said material further comprising an anti-inflammatory agent, such as a steroid or an NSAID, or an additional molecule that impair a bacterial or viral agent, such as a protein that interferes with pathogen attachment, colonization, a protein that enhances immune clearance of said agent, or a conventional antibiotic, such as azithromycin, tobramycin, ciprofloxacin, erythromycin, and amoxicillin.

### Claim 21 (depends on 1)

A method of providing airway intervention to a subject comprising inserting an airway intervention device of claim 1 to subject.

### Claim 22 (depends on 21)

The method of claim 21, wherein said intervention is performed for less than 1 day.

### Claim 23 (depends on 21)

The method of claim 21, wherein said intervention is performed for more than 1 day, such as for a week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks or 10 weeks.

### Claim 24 (depends on 1)

A kit comprising an airway intervention device of claim 1, or the individual components for making such a coated airway intervention device, in sterile packaging.

### Claim 25 (depends on 24)

The kit of claim 24, further comprising instructions for use of said device.

### Claim 26 (depends on 1)

A method of reducing the incidence of subglottic stenosis, pneumonia (VAP), laryngeal infection, post-operative dressing/packing-induced infection, upper airway infection, rhinosinusitis, choanal atresia, or vocal fold injury and paralysis in subjects receiving airway intervention comprising providing airway intervention with an airway intervention device of claim 1.
